Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$37.94 USD
-0.73 (-1.89%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $37.97 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
CORT 37.94 -0.73(-1.89%)
Will CORT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CORT
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Corcept (CORT) Run Higher on Rising Earnings Estimates?
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice
Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?
Other News for CORT
Biotech Alert: Searches spiking for these stocks today
Corcept Therapeutics price target raised by $40 at Canaccord, here's why
Unveiling 8 Analyst Insights On Corcept Therapeutics
Corcept Therapeutics (CORT) Receives a Buy from Truist Financial
Buy Rating Affirmed: Corcept’s Strong Q2 Performance and Promising Pipeline Catalyze Growth